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Several antimicrobial and immunosuppressive effects have been attributed to the statins
class of antihyperlipidemia drugs. Several studies have also indicated clinical benefits for
the use of statins during the management of infections and sepsis. To assess whether
the immunosuppressive effects of statins outweigh their antimicrobial effects during a
fungal infection BALB/c mice were administered Candida albicans via intraperitoneal
injection. These mice received either a co-injection of atorvastatin along with the
infection, were treated with one injection of atorvastatin per day for 5 days prior to
infection, or were infected and then treated with one injection of atorvastatin for 5 days
afterward. Groups that received C. albicans without being treated with atorvastatin were
included as controls along with a group that only received phosphate-buffered saline.
Mouse survival was then monitored; additionally, serum IFN-γ and IL-4 levels were
determined by enzyme linked immunosorbent assay to assess pro-inflammatory and
pro-humoral responses, respectively. Atorvastatin administration was capable of altering
mouse survival rate with the lowest rate (11.1%) being observed in the group treated for
5 days prior to infection with atorvastatin compared to mice infected but not treated with
atorvastatin (44.4%). IFN-γ and IL-4 levels were depressed in all C. albicans-infected
groups treated with atorvastatin. The possibility that statin administration may suppress
or modulate particular components of the immune system during an infection in man
should be further explored in large randomized controlled trials.
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INTRODUCTION
Statins are HMG-CoA reductase inhibitors that interfere with cholesterol biosynthesis and are thus
extensively used in the treatment of hypercholesterolemia. Statins have various pleiotropic eﬀects
that are independent of their serum cholestrol-lowering properties. Some of those reported have
included antioxidative, anti-inﬂammatory and immunomodulatory capabilities (Athyros et al.,
2009). Members of our group have also reported an enhanced graft longevity eﬀect for atorvastatin,
one of the most commonly used statins, in mice and in human transplant recipients; this is
potentially due to atorvastatin’s immunomodulatory properties (El-Haibi et al., 2006; Rahal et al.,
2012a,b; Zeidan et al., 2013).
A number of studies have indicated that statins may also have beneﬁcial eﬀects as therapeutic
agents in infection and sepsis as well as prophylactic agents that reduce the risk of infection. On
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the other hand, some studies have shown no beneﬁcial
eﬀects or even an increased risk of an unfavorable infection
outcome. Moreover, a considerable number of meta-analyses and
systematic reviews have examined the literature on statins and
infection with rather inconclusive results (Falagas et al., 2008;
Gao et al., 2008; Kopterides and Falagas, 2009; Tleyjeh et al., 2009,
2012; Bjorkhem-Bergman et al., 2010; Janda et al., 2010; van den
Hoek et al., 2011; Ma et al., 2012; Wan et al., 2014; Wang et al.,
2014).
Multiple reports indicate that statins have anti-inﬂammatory
and immunomodulatory properties aﬀecting both Th1 and Th2
immune responses (Leung et al., 2003; McKay et al., 2004;
Palaniswamy et al., 2010). Statins were demonstrated to interfere
with the proliferation and activation of a myriad of immune cell
types (Cutts and Bankhurst, 1990; Chakrabarti and Engleman,
1991; Weber et al., 1995; Katznelson et al., 1998; Rudich et al.,
1998). Moreover, the expression of a considerable number of
cytokines (Weber et al., 1997; Liu et al., 1999), adhesionmolecules
and class II human leukocyte antigens (HLA) (Kwak et al., 2000)
was shown to be downregulated by statins (Rosenson et al., 1999;
Kothe et al., 2000; Romano et al., 2000; Wang et al., 2005).
On the other hand, statins appear to decrease the expression of
cyclooxygenase-2 (COX-2) (Yasmin et al., 2012) while potentially
triggering the expression of the rather anti-inﬂammatory Heme-
oxygenase-1 (HO-1) enzyme (Mira et al., 2008). Furthermore,
statins maymodulate inﬂammatory responses by interfering with
nuclear factor kappa B (NFkB) (Wang et al., 2005), peroxisome
proliferator activated receptors (PPAR) and mitogen-activated
protein kinase (MAPK) signaling (Kleemann et al., 2004) among
other pathways.
Our group has previously reported a suppression of certain
aspects of both the humoral and the cell-mediated branches
of immunity in mice challenged with egg albumin upon
treatment with atorvastatin (El-Haibi et al., 2006). We detected a
suppression of IFN-γ and IL-4 production. Therefore, a potential
protective eﬀect of statins against infection, as indicated above,
in light of its immunosuppressive properties is at ﬁrst glance
rather counterintuitive. Hence, we investigated the eﬀects of
atorvastatin on the immune status and on the survival of mice
during a fungal infection. The antifungal properties of statins
are rather well-documented; various mechanisms that relate to
inhibition of ergosterol and isoprenoid-biosynthesis are thought
to result in these antifungal properties. Various statins have
been reported to inhibit the growth of Aspergillus (Macreadie
et al., 2006; Yasmin et al., 2012), Zygomycete (Roze and Linz,
1998), Cryptococcus (Chin et al., 1997), and Candida species
including Candida albicans (Chin et al., 1997; Song et al., 2003).
Mechanisms behind statin-mediated inhibition of fungal growth
probably vary between diﬀerent species. For example, lovastatin-
mediated genetic inhibition of siderophore triacetylfusarinine
C (TAFC), required for iron uptake in Aspergillus fumigatus,
results in attenuated virulence in this organism. This implies that
statin treatment might aﬀect virulence of A. fumigatus also via
inhibition of TAFC biosynthesis and not solely via inhibition of
isoprenoide biosynthesis. This mechanism is not expected to play
a role in fungal species that rely on non-HMGCoA reductase-
dependent siderophores or that do not produce siderophores
such as C. albicans and Cryptococcus neoformans (Yasmin et al.,
2012).
We intended to evaluate whether the immunosuppressive
eﬀects of atorvastatin outweighed its anti-fungal eﬀects. For this
purpose BALB/c mice were infected with C. albicans. Mouse
survival was then monitored. Additionally, IFN-γ and IL-4 were
examined in these mice to assess pro-inﬂammatory and pro-
humoral responses, respectively.
MATERIALS AND METHODS
Atorvastatin and C. albicans
Lipitor R© (Pﬁzer Inc., New York, NY, USA) tablets, each
containing 10 mg of atorvastatin, were pulverized and suspended
in phosphate buﬀered saline (PBS) (Sigma–Aldrich, St. Louis,
MO, USA). The C. albicans American Type Culture Collection
(ATCC) 14053 strain was used in this study. In vitro susceptibility
of this strain to atorvastatin was veriﬁed using Clinical
Laboratory Standards Institute (CLSI) guidelines.
Mouse Treatments and Survival
Monitoring
Mouse studies were approved by the Institutional Animal Care
and Use Committee (IACUC) at the American University of
Beirut prior to initiation of experiments. Five groups of 4–
6 weeks old BALB/c mice, each containing 9 animals, were
used to monitor survival upon atorvastatin treatment and
infection. One group was infected with C. albicans receiving
a co-injection of atorvastatin, a second group received one
injection of atorvastatin per day for 5 days prior to infection
with C. albicans and a third group was infected with C. albicans
then treated with one injection of atorvastatin for 5 days
afterward. A group that was not treated with atorvastatin but
received a single dose of C. albicans was included. In addition
a group that received a single injection of PBS on the day of
infection was used as a negative control since PBS was used to
prepare C. albicans and atorvastatin doses. Mice infected with
C. albicans were injected with 10.8 × 107 colony forming units
(CFUs) intraperitoneally; this infectious dose was selected since
it was sub-LD50 when injected intraperitoneally into BALB/c
mice and allowed for monitoring a variation in death events
upon atorvastatin treatment. Atorvastatin injections were also
administered intraperitoneally with each injection consisting
of 40 mg/Kg, the minimum eﬀective immunomodulatory dose
in BALB/c mice as reported in our previous studies (El-Haibi
et al., 2006). Atorvastatin, C. albicans and PBS injections each
consisted of 0.25 ml. Infected mice were then monitored for
18 days. Upon mouse death, the liver, spleen and heart were
collected, homogenized and cultured to verify that death was due
to systemic infection with C. albicans.
Determination of Mouse Serum IFN-γ
and IL-4 Levels
To assess mouse serum IFN-γ and IL-4 levels, a set of mice
was treated as described above for survival monitoring; however,
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three mice per group were sacriﬁced by cardiac puncture on
day 3 post-C. albicans infection. This day was selected for
cytokine assessment since it occurred 1 day prior to escalation of
death events. Three mice from the PBS-treated group were also
sacriﬁced on day 3 post-injection. Sera were pooled per group
and analyzed for cytokine levels with Single Analyte ELISArray
Kits (Qiagen Inc., Valencia, CA, USA).
Statistical Analysis
The log-rank (Mantel-Cox) test and Kaplan–Meier survival
analysis were conducted using PASW Statistics 18 for Windows.
Two-sample t-tests were used to assess cytokine level variations
with the GraphPad t-test calculator. Mouse groups infected with
C. albicans and treated with atorvastatin were compared to the
mouse group infected with C. albicans but not treated with
atorvastatin. p-values less than 0.05 were considered statistically
signiﬁcant.
RESULTS
Mouse Survival
In C. albicans-infected mice, survival analysis (p < 0.05,
individual treated groups compared to the infected but untreated
group) revealed that the lowest survival rate at the end of the
monitoring period was 11.1%, observed in the group treated for
5 days pre-infection with atorvastatin (Figure 1). The survival
rate at the end of the monitoring period in the group treated
for 5 days post-infection with atorvatstatin was 22.2% while it
was 44.4% in the group of mice that received a single dose of
atorvastatin along with infection. The survival rate of the group
infected with C. albicans but not treated with atorvastatin was
44.4%. Mouse death due to C. albicans infection was veriﬁed via
recovering the organism from mouse liver, spleen, and heart by
culture; no notable diﬀerences in fungal burden were detected
between the statin treated groups and the untreated group upon
culturing the indicated organs.
Mouse Serum IFN-γ and IL-4
Mouse groups infected with C. albicans and treated with
atorvastatin showed a 95-fold decrease in the levels of IFN-γ
on day 3 post-infection compared to the group infected but not
treated with atorvastatin (Figure 2).
All mouse groups infected with C. albicans and treated with
atorvastatin showed a suppressed level of serum IL-4 (Figure 3).
Mice infected with C. albicans and treated with atorvastatin
displayed a 2222-fold decrease in the level of this mediator on
day 3 post-infection compared to mice infected with C. albicans
but not treated with atorvastatin.
DISCUSSION
Various antimicrobial and immunomodulatory eﬀects have been
described for the statins class of antihyperlipidemia drugs.
In addition, several studies have indicated clinical beneﬁts
for the use of statins during the management of infections
and sepsis in human subjects. We therefore used a mouse
model of fungal infection to assess whether the previously
described immunosuppressive eﬀects of statins outweigh their
anti-microbial eﬀects during an infection. In particular, we
examined the eﬀects of atorvastatin, one of the most commonly
prescribed statins.
We observed that treatment of C. albicans-infected mice with
atorvastatin was capable of decreasing survival depending on
the regimen employed. IFN-γ and IL-4 levels were suppressed
by atorvastatin treatment independent of the treatment mode.
We did not detect any notable diﬀerences in fungal burden
between the statin treated groups and the untreated group
upon culturing harvested organs; this may indicate that the
immunosuppressive eﬀects detected were suﬃcient to overcome
the antifungal properties of the atorvastatin. Higher doses of
atorvastatin may have allowed better tissue distribution and
prevented organism proliferation within organ tissues; however,
such doses would have been outside of the range used for therapy
in humans.
In our previous studies on BALB/c mice atorvastatin reduced
the expression of IFN-γ when mice were challenged with
albumin (El-Haibi et al., 2006) but not when they received skin
allografts from C57BL/6 mice (Zeidan et al., 2013). Hence, a
decrease of IFN-γ may be dependent on the challenge itself
and whether it can overcome atorvastatin suppression. For
example, in a study investigating the in vitro role of ﬂuvastatin in
Mycobacterium tuberculosis infection in human peripheral blood
mononuclear cells, ﬂuvastatin was found to enhance the Th1
protective response to the infection (Montero et al., 2000). The
proposed mechanism for this eﬀect was an increased activity of
Caspase I. This protease converts pro-IL-1β and −18 into their
biologically active forms, which in turn act synergistically with
IL-12 to induce IFN-γ release; this study found that ﬂuvastatin,
in the presence of an M. tuberculosis infection, enhances the
activity of Caspase I, ultimately leading to an increase in IFN-γ
production and therefore giving the immune response a Th1 bias.
It has also been shown that statins, including atorvastatin, repress
the expression of MHC II molecules induced by IFN-γ, thereby
impairing T-cell activation and compromising the adaptive
immune response (Kwak et al., 2000). Moreover, simvastatin was
shown to suppress the expression of Toll-like receptor (TLR) 4 on
human monocytes in vivo in response to LPS treatment; this was
associated with reduced tumor necrosis factor-α and monocyte
chemoattractant protein-1 levels (Niessner et al., 2006). A similar
eﬀect was also observed in human CD14+ monocytes treated
with atorvastatin, whereby TLR 4 expression was signiﬁcantly
down-regulated (Methe et al., 2005). Hence, upon atorvastatin
treatment, whether IFN-γ levels rise or are suppressed in
response to a challenge, other aspects of the immune response,
including those downstream to IFN-γ, may be impaired. This
would result in an inadequate immune response.
All groups treated with atorvastatin had a severe decrease in
the levels of the assessed cytokines regardless of the mode of
treatment. This corresponded with decreased survival rates in
groups of mice treated with atorvastatin for 5 days before or
after infection. This indicates that the enhanced death is likely
due to the immunosuppressive eﬀects of this agent overcoming
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FIGURE 1 | Cumulative survival of mice infected with Candida albicans and treated with atorvastatin. BALB/c mice received an injection of C. albicans
and were treated either with a single co-injection of atorvastatin, 5 days pre-infection or a 5 days post-infection atorvastatin regimen. A group infected with
C. albicans but not treated with atorvastatin was also included. A mouse group injected solely with PBS, as a negative control, showed a 100% survival rate (not
shown). Day 0 indicates the day of infection. Mice were monitored for 18 days after infection.
its anti-fungal eﬀects. On the other hand, despite the decrease
in detection of IFN-γ and IL-4 in the group of mice receiving
a single dose of atorvastatin along with infection, death rates
were not enhanced in this group. This may indicate that other
components of the immune system are aﬀected by a prolonged
treatment with atorvastatin resulting in the enhanced death rates
seen in the groups of mice treated for 5 days with atorvastatin
before or after infection. Components of the immune response
previously reported to play major roles in combating C. albicans
infections that may have been aﬀected by this prolonged
treatment include Th17 and neutrophil responses. Multiple
studies indicate that these components are modulated by statin
treatment. Pravastatin, simvastatin, and atorvastatin were shown
to reduce neutrophil transendothelial migration (Maher et al.,
2009) and lovastatin was reported to aﬀect leukocyte mobilization
and result in a Th1 to Th2 shift in a heat-inactivated Candida
albicans delayed type hypersensitivity mouse model (Mira et al.,
2008). Moreover, simvastatin was demonstrated to enhance
neutrophil apoptosis (Chello et al., 2007). Atorvastatin, among
other statins, was also shown to decrease Th17 responses in
various models and in humans (Aktunc et al., 2011; Li et al., 2011;
Jameel et al., 2013; Lappegard et al., 2013). Although the survival
rate of the group receiving a single injection of atorvastatin along
with infection was similar to the group that received the infection
alone by the end of the monitoring period, the death events in the
former group occurred at a slower pace. This may indicate that
the atorvastatin anti-microbial properties have an eﬀect at this
dose that is ultimately insuﬃcient or eventually overwhelmed by
the immunosupressed state of the mice.
Worth noting is that the dose of each atorvastatin injection
administered to mice in the study at hand, 40 mg/Kg, is
equivalent to a dose of 3.24 mg/Kg in man based on United
States Food and Drug Administration (FDA) mouse to human
dose translation guidelines (Reagan-Shaw et al., 2008). This dose
is therefore about 2.5X that currently recommended per day for
the treatment of most human subjects. We used this dose since it
was the lowest to have an immunomodulatory eﬀect in BALB/c
mice in our previous studies (El-Haibi et al., 2006). Moreover,
these previous studies have shown that this dose of atorvastatin
is not lethal to the mice by itself. While the dose we employed is
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FIGURE 2 | Serum IFN-γ levels in mice infected with C. albicans and treated with atorvastatin. BALB/c mice received an injection of C. albicans and were
treated either with a single co-injection of atorvastatin, 5 days pre-infection or a 5 days post-infection atorvastatin regimen. A group that was infected with
C. albicans but not treated with atorvastatin was included in addition to a group injected solely with PBS, as a negative control. Mouse sera were then assessed for
IFN-γ levels by ELISA on day 3 post infection. ∗ indicates p < 0.05 compared to the C. albicans-infected group.
FIGURE 3 | Serum IL-4 levels in mice infected with C. albicans and treated with atorvastatin. BALB/c mice received an injection of C. albicans and were
treated either with a single co-injection of atorvastatin, 5 days pre-infection or 5 days post-infection atorvastatin regimen. A group that was infected with C. albicans
but not treated with atorvastatin was included in addition to a group injected solely with PBS, as a negative control. Mouse sera were then assessed for IL-4 levels
by ELISA on day 3 post infection. ∗ indicates p < 0.05 compared to the C. albicans-infected group.
higher than the one typically employed in man, similar high daily
doses have been used in some subject groups (Cilla et al., 1996)
and multi-dosing has been reported to result in cumulative blood
level spikes (Lins et al., 2003).
A decrease in sepsis-associated mortality rate in human
subjects on statins was presumed to be an eﬀect of the
immunomodulatory and anti-inﬂammatory properties
of these drugs. In murine models (Merx et al., 2005;
Yasuda et al., 2006; Chaudhry et al., 2008; Rosch et al.,
2010; Shinozaki et al., 2010), statins appeared to improve
animal survival rates after septic shock induced by LPS
challenge, bacterial infection or cecal ligation and puncture
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and pravastatin has been shown to enhance the survival of
C. albicans- challenged mice (Tashiro et al., 2012). Chaudhry
et al. (2008) have demonstrated that mice challenged with
LPS have signiﬁcantly lower serum TNF-α and IL-6, the pro-
inﬂammatory cytokines, upon cerivastatin treatment. On the
other hand, animals challenged with live Staphylococcus aureus
or Salmonella enterica serovar Typhimurium did not display a
signiﬁcant decrease in TNF-α or IL-6 levels after treatment.
Although some studies have described potential beneﬁts for
statin use during a Candida infection both in mice (Tashiro
et al., 2012) and in a clinical setting (Forrest et al., 2010;
Spanakis et al., 2010; Cuervo et al., 2013), our ﬁndings added
to the observations denoted above indicate that the eﬀects of
statins may be dependent on the type of infection and the agent
administered itself in addition to the statin regimen employed.
The study by Tashiro et al. (2012), indicated above, reported
enhanced survival and a decreased fungal burden in C3H/HeN
mice infected with C. albicans treated with pravastatin. We did
not see a similar eﬀect in BALB/c mice treated with atorvastatin.
This underscores the notion that diﬀerent statins may result in
diﬀerent outcomes potentially in a host and regimen-dependent
manner. Further studies will tackle mechanisms upstream of
cytokine level modulation that are diﬀerently aﬀected in a
challenge-dependent manner upon statin treatment. Prominent
candidates for examination are members of the TLR family
of receptors, some of the ﬁrst responders that recognize non-
host molecules; as described above, evidence indicates that TLR
moleculesmay be aﬀected by statin treatment which rather brings
them to the forefront. Moreover, cellular responses downstream
of the assessed cytokines resulting in decreased animal survival
should also be examined. Therefore, statins are potentially
deleterious to the health and survival of a subject during
an infection. Their administration may suppress or modulate
particular components of the immune system. This possibility
should be taken into account and further explored in large
randomized controlled trials.
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